Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. Companies specializing in drug ...

FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...

NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Fortrea met analysts’ revenue expectations ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12.00 in a report issued on Tuesday,Benzinga reports. The firm presently has ...

Fortrea Holdings Inc (NASDAQ:FTRE) achieved a strong book-to-bill ratio of 1.35 in the fourth quarter, indicating robust demand and successful sales efforts. The company's backlog has grown to $7. ...